According to the monitoring of adverse drug reactions, the State Food and Drug Administration issued an announcement on its website recently, requiring drug manufacturers to revise the formulation of reporcitin mesylate as soon as possible, and increase the relevant safety content. Caution: Patients taking this product may appear With self-mutilation or suicidal thoughts, adults younger than 25 years are at higher risk of suicidal behavior; products are usually not used in patients under the age of 18 and elderly patients; pregnant and lactating women ban products.

Reboxetine Mesylate is mainly used for the treatment of depression in adults. The product is divided into capsule and tablet dosage forms, and the common product on the market is called “Yelo抒”.

The State Food and Drug Administration stipulates that the newly revised specification should be added in the “Notes”: This product should be taken under the guidance of a doctor and should not be provided to other patients with depression; if the adverse reactions increase or new adverse reactions occur, it should be Immediately inform the doctor; the patient's family members and caregivers must closely observe the clinical symptoms, suicidal tendencies, and abnormal behavior changes after the patient's antidepressant treatment, and communicate with the doctor in a timely manner; the patient should not drive or operate the machine while taking this product.

The State Food and Drug Administration requires that the relevant drug manufacturer should amend the contents of the manual and label as soon as possible, record in accordance with the relevant regulations, notify the relevant medical institutions, drug management companies, etc. of the revised content, and actively track the safety of the clinical application of the drug. Adverse reactions were collected as required and reported in a timely manner.